{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:43:53Z","timestamp":1778791433132,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.euroneuro.2022.03.010","type":"journal-article","created":{"date-parts":[[2022,5,8]],"date-time":"2022-05-08T23:12:57Z","timestamp":1652051577000},"page":"36-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Comparative effectiveness of antipsychotic monotherapy and polypharmacy in schizophrenia patients with clozapine treatment: A nationwide, health insurance data-based study"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6555-9110","authenticated-orcid":false,"given":"Sung Woo","family":"Joo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Tak","family":"Jo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4413-5025","authenticated-orcid":false,"given":"Soojin","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Jae","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8930-3774","authenticated-orcid":false,"given":"Woohyeok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jungsun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2022.03.010_bib0001","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.euroneuro.2013.04.010","article-title":"Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching","volume":"23","author":"Agid","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0002","series-title":"Cochrane Database of Systematic Reviews","article-title":"Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia","author":"Barber","year":"2017"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0003","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/schbul\/sbn030","article-title":"Does the addition of a second antipsychotic drug improve clozapine treatment?","volume":"35","author":"Barbui","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0004","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v64n0416","article-title":"Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study","volume":"64","author":"Ciapparelli","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0005","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1017\/S0033291717000435","article-title":"Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors","volume":"47","author":"Demjaha","year":"2017","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0006","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/bjb.2018.67","article-title":"Barriers to using clozapine in treatment-resistant schizophrenia: systematic review","volume":"43","author":"Farooq","year":"2019","journal-title":"BJPsych Bull."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0007","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1017\/S1461145712000399","article-title":"Critical review of antipsychotic polypharmacy in the treatment of schizophrenia","volume":"17","author":"Fleischhacker","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0008","doi-asserted-by":"crossref","DOI":"10.5620\/eht.e2015012","article-title":"Utilization of health insurance data in an environmental epidemiology","volume":"30","author":"Ha","year":"2015","journal-title":"Environ. Health Toxicol."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0009","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0010","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","article-title":"Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation","volume":"201","author":"Howes","year":"2012","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0011","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0012","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/pcn.12275","article-title":"Psychotropic dose equivalence in Japan","volume":"69","author":"Inada","year":"2015","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0013","first-page":"1","article-title":"Antipsychotic treatment and risk of discontinuation and hospitalization in first-episode schizophrenia: a nationwide population-based study","author":"Joo","year":"2021","journal-title":"Psychol. Med."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0014","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and management of treatment-resistant schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0015","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","article-title":"The social and economic burden of treatment-resistant schizophrenia: a systematic literature review","volume":"29","author":"Kennedy","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0016","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3346\/jkms.2017.32.5.718","article-title":"Towards actualizing the value potential of korea health insurance review and assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data","volume":"32","author":"Kim","year":"2017","journal-title":"J. Korean Med. Sci."},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2022.03.010_bib0017","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD method","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0018","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.schres.2010.10.026","article-title":"Trajectories of the course of schizophrenia: from progressive deterioration to amelioration over three decades","volume":"126","author":"Levine","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0019","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1203241","article-title":"Medication for attention deficit-hyperactivity disorder and criminality","volume":"367","author":"Lichtenstein","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.schres.2019.05.030","article-title":"Switching to antipsychotic monotherapy vs. staying on antipsychotic polypharmacy in schizophrenia: a systematic review and meta-analysis","volume":"209","author":"Matsui","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0021","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1192\/apt.bp.110.008128","article-title":"Underuse of clozapine in treatment-resistant schizophrenia","volume":"17","author":"Mistry","year":"2011","journal-title":"Adv. Psychiatr. Treat."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0022","series-title":"National Institute for Health and Clinical Excellence: guidance, Psychosis and Schizophrenia in Adults: treatment and Management: updated Edition 2014","author":"National Collaborating Centre for Mental","year":"2014"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0023","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.euroneuro.2014.01.014","article-title":"Quality of prescribing for schizophrenia: evidence from a national audit in England and Wales","volume":"24","author":"Patel","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-019-0090-z","article-title":"The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research","volume":"6","author":"Potkin","year":"2020","journal-title":"NPJ Schizophr."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13033-016-0077-3","article-title":"Mental health services and R&D in South Korea","volume":"10","author":"Roh","year":"2016","journal-title":"Int. J. Ment. Health Syst."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0026","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1093\/schbul\/sbab063","article-title":"Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study","volume":"47","author":"Rubio","year":"2021","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0027","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamapsychiatry.2015.2955","article-title":"Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia: a network meta-analysis","volume":"73","author":"Samara","year":"2016","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0028","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0029","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1177\/0706743717718167","article-title":"Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis","volume":"62","author":"Siskind","year":"2017","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0030","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1177\/0004867418772351","article-title":"Augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis","volume":"52","author":"Siskind","year":"2018","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0031","series-title":"Prescriber's Guide: Stahl's Essential Psychopharmacology","author":"Stahl","year":"2020"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0032","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1093\/schbul\/sbx176","article-title":"Comparative effectiveness of antipsychotic drugs for rehospitalization in schizophrenia\u2014a nationwide study with 20-year follow-up","volume":"44","author":"Taipale","year":"2017","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0033","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0034","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S2215-0366(22)00069-4","article-title":"The promise and pitfalls of antipsychotic co-initiation in schizophrenia","volume":"9","author":"Takeuchi","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0447.2011.01792.x","article-title":"Augmentation of clozapine with a second antipsychotic \u2013 a meta-analysis","volume":"125","author":"Taylor","year":"2012","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0036","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamapsychiatry.2017.1322","article-title":"Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29\u00a0823 patients with schizophrenia","volume":"74","author":"Tiihonen","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0037","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamapsychiatry.2018.4320","article-title":"Association of antipsychotic polypharmacy vs monotherapy with psychiatric rehospitalization among adults with schizophrenia","volume":"76","author":"Tiihonen","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0038","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/appi.ajp.2018.17091001","article-title":"20-year nationwide follow-up study on discontinuation of antipsychotic treatment in first-episode schizophrenia","volume":"175","author":"Tiihonen","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0039","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/schbul\/sbp149","article-title":"Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis","volume":"37","author":"Uchida","year":"2011","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0040","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/acps.12621","article-title":"Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study","volume":"134","author":"Vanasse","year":"2016","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2022.03.010_bib0041","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/acps.13280","article-title":"An evaluation of the variation and underuse of clozapine in the United Kingdom","volume":"143","author":"Whiskey","year":"2021","journal-title":"Acta Psychiatr. Scand."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22001687?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X22001687?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:02:18Z","timestamp":1760378538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X22001687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":41,"alternative-id":["S0924977X22001687"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.03.010","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness of antipsychotic monotherapy and polypharmacy in schizophrenia patients with clozapine treatment: A nationwide, health insurance data-based study","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2022.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}